Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine (replaced by TA217) (TA111)
Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease
This guidance has been updated and replaced by TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine
This guidance updates and replaces NICE technology appraisal 19 (published in January 2001)
This page was last updated: 13 February 2014
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.